Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.74 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.74 |
| ▸ | USP7 | Q93009 | 2/20 | 0.74 |
| ▸ | STAT3 | P40763 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.66 |
| ▸ | NOS2 | P35228 | 7/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200341 | 1.00 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL83735 | 0.92 | NFE2L2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12125024 | 0.92 | NFE2L2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL15382999 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL15382991 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447444 | 0.91 | NFE2L2 (0.62) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82945 | 0.91 | NOS2 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447479 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82937 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL13393866 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9701709-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9556222-B2 | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9278913-B2 | Therapeutic compounds and methods of use | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2016-03-08 | — | — | US | disclosed |
| US-9249089-B2 | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives | REATA PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9233998-B2 | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9205113-B2 | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150259377-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20110245206-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | REATA PHARMACEUTICALS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-7943778-B2 | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives | REATA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7915402-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | REATA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | NFE2L2 1232/4885MBOAT4 3110/4885USP7 2231/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NFE2L2 315/4885MBOAT4 1458/4885USP7 4046/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NFE2L2 1455/4885MBOAT4 1132/4885USP7 3609/4885 |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885MBOAT4 415/4885USP7 484/4885 |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NFE2L2 4/4885MBOAT4 650/4885USP7 1310/4885 |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | IL17A, ALOX15, ALOX12 | NFE2L2 6/4885MBOAT4 500/4885USP7 753/4885 |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | ALOX12, NFE2L2, HMOX1 | NFE2L2 2/4885MBOAT4 658/4885USP7 2396/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885MBOAT4 415/4885USP7 484/4885 |
| US-20150259377-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | NFE2L2 437/4885MBOAT4 3396/4885USP7 1030/4885 |
| US-20110245206-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | IL17A, ALOX15, ALOX12 | NFE2L2 6/4885MBOAT4 500/4885USP7 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.